AGPAT1: A Potential Drug Target or Biomarker (G10554)

Target Name: AGPAT1

NCBI ID: G10554

AGPAT1

AGPAT1: A Potential Drug Target or Biomarker

AGPAT1 (1-acylglycerol-3-phosphate O-acyltransferase 1) is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and muscle. It is a key enzyme in the pathway of acetoacetyl-CoA thiolase, which is involved in the production of both acetyl-CoA and thiolase activity. The AGPAT1 gene has been identified as a potential drug target or biomarker for several diseases, including diabetes, cancer, and neurodegenerative diseases.

The AGPAT1 gene is located on chromosome 16 at position 662.3 and encodes a protein with 215 amino acid residues. The protein has a molecular weight of 29.1 kDa and a pre-protein N-terminal extension of 15 amino acids. AGPAT1 is predominantly expressed in the liver, with a significant level of expression also observed in pancreas and muscle. The protein is expressed in both the cytoplasm and the endoplasmic reticulum, and is also detectable in the cell surface.

AGPAT1 is involved in the production of acetyl-CoA, which is a critical precursor for the synthesis of many essential compounds, including steroids, sex hormones, and drugs. The production of acetyl-CoA from pyruvate is a critical step in the citric acid cycle, and AGPAT1 plays a crucial role in this process by transferring the acetyl group from pyruvate to the carbonyl group of CoA. This transfer of the acetyl group allows the CoA to be converted into its more compact form, acetyl-CoA, which can then be used as a precursor for the synthesis of other molecules.

In addition to its role in the production of acetyl-CoA, AGPAT1 is also involved in the regulation of cellular processes. For example, the protein has been shown to play a role in the regulation of cell growth, and is expressed in high levels in tissues that are characterized by rapid cell growth, such as the liver and pancreas. This suggests that AGPAT1 may be a potential drug target for diseases that are characterized by uncontrolled cell growth, such as cancer.

AGPAT1 has also been shown to be involved in the regulation of inflammation. The protein has been shown to play a role in the production of pro-inflammatory cytokines, such as TNF-alpha and IL-18. This suggests that AGPAT1 may be a potential drug target for diseases that are characterized by inflammation, such as autoimmune diseases or inflammatory bowel disease.

Despite its potential as a drug target or biomarker, AGPAT1 has not yet been studied extensively, and more research is needed to fully understand its role in cellular processes. Additionally, the precise mechanism by which AGPAT1 is involved in the production of acetyl-CoA and the regulation of cellular processes is not yet fully understood, and further research is needed to determine its precise function.

In conclusion, AGPAT1 is a protein that is involved in the production of acetyl-CoA and the regulation of cellular processes. With its potential as a drug target or biomarker, AGPAT1 makes it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand its role in cellular processes and to determine its precise function as a drug target or biomarker.

Protein Name: 1-acylglycerol-3-phosphate O-acyltransferase 1

Functions: Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone

The "AGPAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGPAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets